AKT1 and neoplasm: Aberrant mutations enable tumor cells to acquire this metabolic state, and the most studied aberrant mutations belong to the myelocytomatosis oncogene (MYC) and phosphoinositide 3-kinase (PI3K)–protein kinase B (Akt)–mammalian target of rapamycin (mTOR) signaling pathways.